Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on September 9, 2015. The report discloses the entry into a material definitive agreement regarding the expansion of the Company's office lease in Westlake Village, California.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The financial details are limited to the terms of the amended lease agreement:
- Lease Expansion: The Company increased its rentable square footage by 7,600 sq. ft. (Additional Space) effective September 15, 2015, and exercised an option for an additional 2,937 sq. ft. (Expansion Space).
- Lease Term: The term for all premises was extended to expire on April 30, 2019.
- Base Rent: The base rent per square foot is set at $2.00 from September 15, 2015, through January 31, 2016, with scheduled increases to $2.25 by February 1, 2019.
- Operating Costs: The Company's percentage share of basic costs increased from 4.51% to 11.59% upon delivery of the Additional Space, and will further increase to 14.3% upon delivery of the Expansion Space.
Material Changes
The primary material change is the amendment to the existing office lease to accommodate business growth. The Company is expanding its physical footprint in Westlake Village, California, and extending the lease duration by approximately 13 months compared to the original expiration date of March 31, 2018.
Outlook, Risks, and Management Commentary
Management intends to file the full text of the Amendment and the Lease as exhibits to the Quarterly Report on Form 10-Q for the quarter ending September 30, 2015. The filing notes that the summary provided is qualified in its entirety by reference to the actual legal documents. No specific risks, contingencies, or unusual items beyond the standard lease obligations are detailed in this report.
Investor Verification Checklist
- Verify the total committed lease obligation by calculating the rent for the expanded square footage over the extended term through April 2019.
- Review the upcoming Form 10-Q for the full text of the First Amendment to Lease and the original Lease agreement.
- Confirm the timeline for the "Substantial Completion" of the Expansion Space to determine when the 14.3% cost share becomes effective.
- Assess the impact of the increased fixed operating costs on the Company's cash burn rate given the lack of revenue data in this filing.